Supreme Court urged to review ‘skinny labeling’

Taking stock of the drug industry, from the lab to the medicine chest

December 9, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Solicitor general urges Supreme Court to review 'skinny labeling' and generic drug access The legal skirmish began when Amarin filed a lawsuit five years ago accusing Hikma Pharmaceuticals of infringing three patents By Ed Silverman STAT+ | Opinion: FDA drug center's new acting director fits a pattern of risky, internal contradictions among agency leadership The FDA is tightening evidence demands for some products while loosening them for others. Expert says growing contradictions reflect ideology, not science. By Paul Knoepfler Opinion: It's past time to update the rules intended to slow the FDA's revolving door Current post-employment rules fail to prevent the appearance (and too often the reality) of regulatory capture, especially with the FDA. By Lee Rosebush and Marc Wagner

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser